Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA
-
- Revance gains access to the growing
- Fast-tracks Revance’s commercial organization, and strengthens the anticipated launch of DaxibotulinumtoxinA for Injection (DAXI), the company’s next-generation neuromodulator -
- Conference call and webcast today at
TEOXANE’s RHA® and the Distribution Agreement
Under the distribution agreement announced today, Revance will gain immediate and exclusive rights to commercialize TEOXANE’s RHA® line of fillers in the U.S., starting with the
Revance believes the RHA® dermal filler line, in combination with the company’s next-generation neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), will position the company to be the innovation leader in the
The agreement also includes a fourth product, RHA® 1, currently in clinical trials in the U.S. with
In consideration for the U.S. distribution rights for all of the above mentioned, Revance has agreed to issue 2.5 million shares of Revance common stock to
“This is a transformational deal for Revance, giving us access to the fast-growing, billion-dollar U.S. dermal filler market, with a line of highly differentiated fillers that are complementary to our first and only, long-lasting neuromodulator,” said
“We are eager to introduce U.S. physicians and consumers to our exciting, highly differentiated RHA® range of dermal fillers,” said Valérie Taupin, Founder and Chief Executive Officer of
Revance has begun the build-out of a U.S. commercial organization and is targeting the introduction of the TEOXANE RHA® fillers in the second quarter of 2020, followed by the launch of DAXI, upon regulatory approval, in the second half of 2020. According to
Conference Call
Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 7659336; or from the webcast link in the investor relations section of the company’s website at: www.revance.com. A replay of the call will be available beginning
About Dermal Fillers in
Dermal fillers are injected into the superficial and deep layers of the skin to restore volume, smooth lines, provide facial lift and contour, plump the lips or improve the appearance of facial scars commonly caused by acne. Hyaluronic acid (HA) dermal fillers represent 88% of the total U.S. dermal filler market and are the second most frequently preformed non-surgical aesthetic treatment after neuromodulator injections.
Hyaluronic acid is naturally found in the body, primarily in the skin, joints and connective tissue. With age, human skin loses its ability to produce HA, resulting in loss of volume, firmness and elasticity. HA dermal fillers are manufactured from synthesized hyaluronic acid crosslinked to significantly enhance durability in the skin. These products can restore lost volume for six to 12 months or longer before the body gradually and naturally absorbs the HA. *** Most HA dermal fillers also contain lidocaine to help minimize discomfort during and after treatment.
The US dermal filler market is estimated to be
About
Moreover, with its scientific expertise, TEOXANE is one of the first Swiss laboratories offering a range of innovative cosmeceutical care formulated with cross-linked hyaluronic acid from its patented process, RHA resilient hyaluronic acid®. The cosmeceutical range, TEOXANE, is designed for patients who have undergone aesthetic medical procedures and continue their skin care with a targeted cosmetic routine designed specifically for them. For more information go to www.TEOXANE.com.
About
“Revance Therapeutics” and the Revance logo are registered trademarks of
1 RHA® is a trademark of
Please refer to the Instructions for Use (https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170002C.pdf). It is the practitioner’s full responsibility to read and inform the patient about contraindications, warnings, precautions, risks and benefits.
2 RHA® 2 and RHA® 3 clinical study G140028: Study 1302: A Controlled, Randomized, Double- Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA 2 and TEOSYAL® RHA 3 versus Juvéderm® Ultra XC in the Treatment of Moderate to Severe Nasolabial Folds.
RHA® 4 clinical study G140106: Study 1402: A Controlled, Randomized, Double- Blinded, Within Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA 4 versus Perlane-L® in the Treatment of Moderate to Severe Nasolabial Folds.
*Sources:
DRG Report Aesthetic Injectables | Market Insights |
**Source: https://www.surgery.org/sites/default/files/ASAPS-Stats2018_0.pdf
ASAPS-Stats2018-Proof5e - surgery.org
***Source: https://www.fda.gov/medical-devices/cosmetic-devices/dermal-fillers-approved-center-devices-and-radiological-health
****Source: DRG –
“Revance Therapeutics” and the Revance logo are registered trademarks of
BOTOX® is a registered trademark of
TEOXANE® is a registered trademark of
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the anticipated strategic and financial benefits of our exclusive distribution agreement with
View source version on businesswire.com: https://www.businesswire.com/news/home/20200110005110/en/
Source:
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
laurence@gilmartinir.com
MEDIA
Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476
sfahy@revance.com
or
General Media:
Y&R:
Jenifer Slaw, 347-971-0906
jenifer.slaw@YR.com
or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com